119 related articles for article (PubMed ID: 7639018)
1. Effect of DETOX as an adjuvant for melanoma vaccine.
Schultz N; Oratz R; Chen D; Zeleniuch-Jacquotte A; Abeles G; Bystryn JC
Vaccine; 1995 Apr; 13(5):503-8. PubMed ID: 7639018
[TBL] [Abstract][Full Text] [Related]
2. Effect of cell wall skeleton and monophosphoryl lipid A adjuvant on the immunogenicity of a murine B16 melanoma vaccine.
Johnston D; Bystryn JC
J Natl Cancer Inst; 1991 Sep; 83(17):1240-5. PubMed ID: 1870150
[TBL] [Abstract][Full Text] [Related]
3. Active-specific immunotherapy for melanoma.
Mitchell MS; Harel W; Kempf RA; Hu E; Kan-Mitchell J; Boswell WD; Dean G; Stevenson L
J Clin Oncol; 1990 May; 8(5):856-69. PubMed ID: 2139701
[TBL] [Abstract][Full Text] [Related]
4. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.
Eton O; Kharkevitch DD; Gianan MA; Ross MI; Itoh K; Pride MW; Donawho C; Buzaid AC; Mansfield PF; Lee JE; Legha SS; Plager C; Papadopoulos NE; Bedikian AY; Benjamin RS; Balch CM
Clin Cancer Res; 1998 Mar; 4(3):619-27. PubMed ID: 9533529
[TBL] [Abstract][Full Text] [Related]
5. Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine.
Oratz R; Dugan M; Roses DF; Harris MN; Speyer JL; Hochster H; Weissman J; Henn M; Bystryn JC
Cancer Res; 1991 Jul; 51(14):3643-7. PubMed ID: 2065322
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with toxofilin DNA in combination with an alum-monophosphoryl lipid A mixed adjuvant induces significant protective immunity against Toxoplasma gondii.
Song P; He S; Zhou A; Lv G; Guo J; Zhou J; Han Y; Zhou H; Hao Z; Cong H
BMC Infect Dis; 2017 Jan; 17(1):19. PubMed ID: 28056837
[TBL] [Abstract][Full Text] [Related]
7. Effect of monophosphoryl lipid A (MPL) on T-helper cells when administered as an adjuvant with pneumocococcal-CRM197 conjugate vaccine in healthy toddlers.
Vernacchio L; Bernstein H; Pelton S; Allen C; MacDonald K; Dunn J; Duncan DD; Tsao G; LaPosta V; Eldridge J; Laussucq S; Ambrosino DM; Molrine DC
Vaccine; 2002 Nov; 20(31-32):3658-67. PubMed ID: 12399193
[TBL] [Abstract][Full Text] [Related]
8. Enhancing activity of mycobacterial cell-derived adjuvants on immunogenicity of recombinant human hepatitis B virus vaccine.
Koike Y; Yoo YC; Mitobe M; Oka T; Okuma K; Tono-oka S; Azuma I
Vaccine; 1998 Dec; 16(20):1982-9. PubMed ID: 9796054
[TBL] [Abstract][Full Text] [Related]
9. Optimization of intracerebral tumour protection by active-specific immunization against murine melanoma B16/G3.12.
Staib L; Harel W; Mitchell MS
Melanoma Res; 2001 Aug; 11(4):325-35. PubMed ID: 11479420
[TBL] [Abstract][Full Text] [Related]
10. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of tumor cell vaccine after incorporating monophosphoryl lipid A (MPL) in tumor cell membranes containing tumor-associated ganglioside.
Ravindranath MH; Brazeau SM; Morton DL
Experientia; 1994 Jul; 50(7):648-53. PubMed ID: 8033972
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the immunoprophylactic potential of a killed vaccine candidate in combination with different adjuvants against murine visceral leishmaniasis.
Thakur A; Kaur H; Kaur S
Parasitol Int; 2015 Feb; 64(1):70-8. PubMed ID: 25316605
[TBL] [Abstract][Full Text] [Related]
13. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.
Cluff CW
Adv Exp Med Biol; 2010; 667():111-23. PubMed ID: 20665204
[TBL] [Abstract][Full Text] [Related]
14. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma.
Morton DL
Dev Biol (Basel); 2004; 116():209-17; discussion 229-36. PubMed ID: 15603194
[TBL] [Abstract][Full Text] [Related]
15. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model.
Jones RC; Kelley M; Gupta RK; Nizze JA; Yee R; Leopoldo Z; Qi K; Stern S; Morton DL
Ann Surg Oncol; 1996 Sep; 3(5):437-45. PubMed ID: 8876885
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of a polyvalent melanoma antigen vaccine in humans.
Bystryn JC; Oratz R; Harris MN; Roses DF; Golomb FM; Speyer JL
Cancer; 1988 Mar; 61(6):1065-70. PubMed ID: 3342366
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.
Wang F; Bade E; Kuniyoshi C; Spears L; Jeffery G; Marty V; Groshen S; Weber J
Clin Cancer Res; 1999 Oct; 5(10):2756-65. PubMed ID: 10537339
[TBL] [Abstract][Full Text] [Related]
18. Clinical activity of a polyvalent melanoma antigen vaccine.
Bystryn JC
Recent Results Cancer Res; 1995; 139():337-48. PubMed ID: 7597302
[TBL] [Abstract][Full Text] [Related]
19. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.
Kruit WH; Suciu S; Dreno B; Mortier L; Robert C; Chiarion-Sileni V; Maio M; Testori A; Dorval T; Grob JJ; Becker JC; Spatz A; Eggermont AM; Louahed J; Lehmann FF; Brichard VG; Keilholz U
J Clin Oncol; 2013 Jul; 31(19):2413-20. PubMed ID: 23715572
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma.
Hersey P; Menzies SW; Halliday GM; Nguyen T; Farrelly ML; DeSilva C; Lett M
Cancer Immunol Immunother; 2004 Feb; 53(2):125-34. PubMed ID: 14600790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]